静脉血栓栓塞症患者的β-抗血水平
Edith Alexandra Uj1,2, Éva Molnár1, Tünde Miklós1,2
1Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei Blvd. 98, 4032 Debrecen, Hungary.
International journal of molecular sciences
|November 27, 2025
概括
较高的β-抗素 (β-AT) 水平与静脉血栓塞栓症 (VTE) 风险的增加有关. 这项研究发现VTE患者的β-AT活性升高,这表明它可能在血栓性疾病中起作用.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 血栓形成研究研究
背景情况:
- β-抗氨酸 (β-AT) 是抗氨酸 (AT) 的高亲和度肝素结合异型,占血AT总量的5-10%.
- 关于血栓性疾病中的β-AT活性存在有限的数据,需要进一步研究其作用.
研究的目的:
- 为了研究和比较静脉血栓栓塞 (VTE) 患者和健康对照者的血β-AT活性水平.
- 确定β-AT水平与静脉瘤风险之间的关联.
主要方法:
- 分析了来自200名VTE患者和200名健康对照者的血样本.
- 使用染色体抗Xa因子测定测量总AT活性.
- 通过使用高盐度 (1.1 M NaCl) 来抑制α-AT氨酸结合的量化β-AT活性.
主要成果:
- 在VTE患者和对照人群之间没有观察到总AT活性的显著差异.
- 与对照组相比,在VTE患者中发现明显更高的β-AT活性水平和β-AT与总AT比率 (p < 0.001).
- 升高的β-AT活性和比率与增加的VTE风险 (OR > 5.7) 有着强烈的关联.
结论:
- 在患有VTE的患者中,血β-AT水平升高.
- 增加β-AT活性可能是VTE的危险因素.
- 需要进一步的研究来阐明VTE中升高β-AT的病理生理学意义.
相关概念视频
Venous Thrombosis III: Interprofessional Care
268
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
268
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
277
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
277
Venous Thrombosis IV: Nursing Management
188
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
188
Venous Thrombosis I: Introduction
321
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
321
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K


